New approaches to target TP53-mutated AML: the ADAPT trial
Andrew Wei, MBBS, PhD, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia, discusses new approaches to target TP53-mutated acute myeloid leukemia (AML), highlighting the potential role of TP53 inactivation and subsequent BCL-xL upregulation in treatment failure after venetoclax-based therapy. Dr Wei explains the rationale and dosing schedule of the ALLG AMLM28/A2 (ADAPT) trial (ACTRN12625000994482p), a Phase Ib/II study evaluating the addition of pelcitoclax (APG-1252) to AML therapy for patients with TP53 aberrations or persistent measurable residual disease (MRD). This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
